HuiGene, a Shanghai Gene Editing Company, Closes $62 Million B Round
publication date: Jun 18, 2021
HuiGene Therapeutics, a Shanghai gene-editing company, closed a $62 million Series B round for its gene editing tools and drug discovery programs based on gene editing for rare diseases. Founded in 2018, HuiGene says it focuses on the CRISPER-Cas editing system, based on the Cas19 protein and targeting ssRNA to edit RNA. Because this technology does not change DNA, the company says it offers better safety than competing gene editing programs. It is carrying out R&D of gene therapies for neurodegenerative diseases, visual disorders, hearing disorders and other diseases. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.